StreetInsider.com News Articles

Form 4 Metagenomi Therapeutics, For: Mar 05 Filed by: Wapnick Pamela

Mon, 09 Mar 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20260309/26133330.html

Form 4 Metagenomi Therapeutics, For: Mar 05 Filed by: Wapnick Pamela

Mon, 09 Mar 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20260309/26133330.html

Form 4 Metagenomi Therapeutics, For: Dec 05 Filed by: Irish Jian

Mon, 09 Mar 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260309/26133320.html

Form 4 Metagenomi Therapeutics, For: Dec 05 Filed by: Irish Jian

Mon, 09 Mar 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260309/26133320.html

Form 4 Metagenomi Therapeutics, For: Mar 05 Filed by: Wein Matthew

Mon, 09 Mar 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260309/26133322.html

Form 4 Metagenomi Therapeutics, For: Mar 05 Filed by: Wein Matthew

Mon, 09 Mar 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260309/26133322.html

Form S-8 Metagenomi Therapeutics,

Thu, 05 Mar 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260305/26119270.html

Form S-8 Metagenomi Therapeutics,

Thu, 05 Mar 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260305/26119270.html

Form 10-K Metagenomi Therapeutics, For: Dec 31

Thu, 05 Mar 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260305/26119118.html

Form 10-K Metagenomi Therapeutics, For: Dec 31

Thu, 05 Mar 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260305/26119118.html

Form 8-K Metagenomi Therapeutics, For: Mar 05

Thu, 05 Mar 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260305/26118946.html

Form 8-K Metagenomi Therapeutics, For: Mar 05

Thu, 05 Mar 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260305/26118946.html

Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results

Thu, 05 Mar 2026 16:05:00 -0400

Completed pre-IND meeting following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs) and remains on track for global regulatory submission including investigational new drug application (“IND”) in 4Q 2026

Announced corporate name change to Metagenomi Therapeutics, Inc. to reflect Company’s strategic evolution

$160.8 million in cash, cash equivalents and available-for-sale marketable securities as of December 31, 2025 with runway anticipated to support operations through 4Q 2027

EMERYVILLE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing

Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results

Thu, 05 Mar 2026 16:05:00 -0400

Announced corporate name change to Metagenomi Therapeutics, Inc. to reflect Company’s strategic evolution

$160.8 million in cash, cash equivalents and available-for-sale marketable securities as of December 31, 2025 with runway anticipated to support operations through 4Q 2027

EMERYVILLE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing

Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference

Mon, 23 Feb 2026 16:05:00 -0400

EMERYVILLE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a fireside chat at the 46^th Annual TD Cowen Healthcare Conference, being held in Boston, MA, on Monday, March 2, 2026 at 11:10 a.m. ET.

The fireside chat presentation will be made available on the “News & Events” page in the Investors section

Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference

Mon, 23 Feb 2026 16:05:00 -0400

The fireside chat presentation will be made available on the “News & Events” page in the Investors section

Form 8-K Metagenomi, Inc. For: Jan 12

Mon, 12 Jan 2026 09:28:00 -0400

si-local-file:///var/storage/secattach/20260112/25835666.html

Form 8-K Metagenomi, Inc. For: Jan 12

Mon, 12 Jan 2026 09:28:00 -0400

si-local-file:///var/storage/secattach/20260112/25835666.html

Metagenomi changes name to Metagenomi Therapeutics, advances hemophilia drug

Mon, 12 Jan 2026 08:30:18 -0400

Metagenomi Inc. (NASDAQ: MGX) announced it has changed its corporate name to Metagenomi Therapeutics Inc. to reflect its focus on advancing later-stage preclinical assets using its gene-editing technologies.

The company reported that its lead hemophilia A treatment, MGX-001, demonstrated curative factor VIII activity in non-human primate studies. The treatment showed dose-dependent activity with no identifiable off-target editing during approximately 19 months of testing using a cynomolgus surrogate FVIII gene.

Metagenomi completed a pre-IND meeting with regulators in the fourth quarter of 2025 for MGX-001. The company plans to submit IND and CTA applications in the fourth quarter of 2026, with first-in-human studies

Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook

Mon, 12 Jan 2026 08:30:00 -0400

New name reflects the Company’s strategic evolution focused on later-stage preclinical assets leveraging its most advanced, signature gene-editing capabilities

Pre-IND meeting held in 4Q 2025 following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs); MGX-001 on track for IND/CTA submissions in 4Q 2026

Cash runway anticipated through 4Q 2027

EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that it has

Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook

Mon, 12 Jan 2026 08:30:00 -0400

New name reflects the Company’s strategic evolution focused on later-stage preclinical assets leveraging its most advanced, signature gene-editing capabilities

Pre-IND meeting held in 4Q 2025 following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs); MGX-001 on track for IND/CTA submissions in 4Q 2026

Cash runway anticipated through 4Q 2027

Form 4 Metagenomi, Inc. For: Dec 05 Filed by: Thomas Brian C.

Mon, 08 Dec 2025 13:56:00 -0400

si-local-file:///var/storage/secattach/20251208/25711641.html

Form 4 Metagenomi, Inc. For: Dec 05 Filed by: Thomas Brian C.

Mon, 08 Dec 2025 13:56:00 -0400

si-local-file:///var/storage/secattach/20251208/25711641.html

Form 4 Metagenomi, Inc. For: Dec 05 Filed by: Wein Matthew

Mon, 08 Dec 2025 13:51:00 -0400

si-local-file:///var/storage/secattach/20251208/25711627.html

Form 4 Metagenomi, Inc. For: Dec 05 Filed by: Wein Matthew

Mon, 08 Dec 2025 13:51:00 -0400

si-local-file:///var/storage/secattach/20251208/25711627.html